Oregovomab

奥戈伏单抗

Report date: 2024/08/02 17:35:54

Base Information

Drug NameOregovomab
Drug Alias NameMonoclonal antibody B43.13Mab B43.13Anti CA125 MabOvaRexB43.13
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionRadionuclide imaging enhancersDendritic cells stimulantsMucin-16 inhibitors
TargetsMucin-16
Therapy Area/IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPancreatic Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[15] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaIND
Originator CompaniesPaladin Pharma
China Registration ClassN/A

Develop Information

Active CompaniesHikma MENA FZECanariaBio IncOrient Europharma Co Ltd +[6] 
Inactive CompaniesUnither PharmaceuticalsAltarexQuest Pharmatech Inc +[4] 
Active IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms +[5] 
Inactive IndicationsPancreatic NeoplasmsAbdominal Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG